Notch is out — your watchlist beside the MacBook notch, synced with this account.
Learn more ↗We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Curient is a biopharmaceutical company specializing in the development of innovative new drugs. It focuses on discovering and developing drug candidates in areas with high unmet medical needs, including oncology and infectious disease treatments. Its key pipeline assets include the Axl/Mer/CSF1R inhibitor Q702 and the CDK7 inhibitor Q901 (both oncology drugs), as well as the tuberculosis treatment Q203.
큐리언트는 혁신 신약 개발을 전문으로 하는 바이오 제약 기업입니다. 항암제 및 감염병 치료제 등 미충족 의료 수요가 높은 분야의 신약 후보 물질을 발굴하고 개발하는 데 주력하고 있습니다. 주요 파이프라인으로는 Axl/Mer/CSF1R 저해제 Q702, CDK7 저해제 Q901(이상 항암제), 그리고 결핵 치료제 Q203 등이 있습니다.
